Trial Information

A PHASE 2, MULTI-CENTER, OPEN-LABEL STUDY OF CINREBAFUSP ALFA (PRS-343) IN COMBINATION WITH RAMUCIRUMAB AND PACLITAXEL IN PATIENTS WITH HER2-POSITIVE GASTRIC OR GASTROESOPHAGEAL (GEJ) ADENOCARCINOMA

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724